Our technology consists of an end-to-end target and therapeutic discovery pipeline – enabling the development of next generation therapies for solid tumors with curative potential. By starting with a productive immune response from patients who have responded to immunotherapy we identify shared targets and therapeutically active TCRs.
3T’s platform addresses two major challenges in immunotherapy development
Path to ID Novel Targets and Profile TCRs for Specificity
3T’s platform covers a broad and genetically diverse patient population to facilitate immunotherapy for the majority of cancer patients
Importantly, this target identification strategy focuses on productive immune responses against cancer and viral infections or immune responses associated with autoimmune diseases, and is termed response-guided target identification.